Blog

Home > Blog > IBSA: STRATEGIC LICENSING AND CDMO PROJECTS FOR THE PHARMACEUTICAL MARKET

IBSA: STRATEGIC LICENSING AND CDMO PROJECTS FOR THE PHARMACEUTICAL MARKET

IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.

Read the Whole Interview

Related Articles

+

05.03.2024

ARTROSIS Y VISCOSUPLEMENTACIÓN – Publirreportaje – Chemistry Today

Artrosis, la causa más frecuente de discapacidad musculoesquelética. Descubramos más con la TECNOLOGÍA HÍBRIDA NAHYCO® de IBSA.

+

05.03.2024

OSTEOARTHRITIS AND VISCOSUPPLEMENTATION – Advertorial – Chemistry today

Osteoarthritis, the most common cause of musculoskeletal disability. Let’s find out more with the IBSA NAHYCO® HYBRID TECHNOLOGY.

+

31.10.2023

Unas palabras con Andrea Taborelli – Entrevista con Chimica Oggi – Chemistry Today

Andrea Toborelli, Director de Desarrollo Empresarial y Licencias de IBSA, fue entrevistado por Nutra Horizons.